NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Canopy Growth Corporation (CGC) Stock Analysis

Canopy Growth Corporation (CGC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

CGC

$0.97

−$0.00 (−0.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGC with… →

CGC Key Statistics

As of Sep 4, 2026
Trading
Open
$0.98
Previous Close
$0.97
Day's Range
0.96–0.98
52-Week Range
0.84–2.38
Volume
1.90M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.43
Valuation
Market Cap
$462.58M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.48
Financials (FY)
Revenue (FY)
$284.60M+5.80%
Net Income (FY)
−$262.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
−79.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
423.04M
1-Year Return
−29.51%
Dividend and dates
Earnings Date
November 6, 2026
Avg Volume
4.05M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CGC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.68%
2025−58.39%
2024−46.38%
2023−77.88%
2022−73.54%
2021−64.57%
2020+16.83%
2019−21.51%
2018+13.59%
2017+246.86%
2016 (partial year)+129.32%

As of September 4, 2026.

CGC Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$284.60M−$262.91M−92.4%
2024$269.00M−$508.88M−189.2%
2023$297.15M−$693.68M−233.4%
2022$333.25M−$3.28B−983.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$284.60M$69.67M−$73.11M−$262.91M−92.4%
2024$269.00M$79.51M−$66.39M−$508.88M−189.2%
2023$297.15M$80.88M−$162.73M−$693.68M−233.4%
2022$333.25M−$63.53M−$395.78M−$3.28B−983.7%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

CGC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricCGCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.582.3031% below
Profit margin−79.22%−3.14%76.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Canopy Growth Corporation (CGC) carries a market capitalisation of $462.58M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 1,128.

The most recent close on file for CGC is $0.97, dated September 4, 2026. That is $0.00 (−0.03%) against the previous close. Over the past 52 weeks the price has ranged from $0.84 to $2.38. The latest close sits 15.25% above that 52-week low.

Financial Health

In fiscal 2025, Canopy Growth Corporation reported revenue of $284.60M. That is +5.80% against the prior fiscal year, when revenue was $269.00M. The same year closed with a net loss of $262.91M. Profit margin runs at −79.22%. That is 76.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.48.

Across the 4 fiscal years on file, revenue moves from $333.25M in 2022 to $284.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.58. On price-to-sales that is 31.4% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −29.51%. Across 10 years the annualized return works out at −28.91%. The reported beta is 2.43. Annualized volatility over the trailing 10 years is 103.21%.

Growth & Income

No dividend is on file for CGC.

So far in 2026 the price is −14.68%. Across the complete calendar years on file, 2017 returned +246.86% and 2023 returned −77.88%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Canopy Growth Corporation (CGC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Canopy Growth Corporation CGC $462.58M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 19.6

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.1x. Canopy Growth Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Visit website →